Attention deficit hyperactivity disorder (ADHD) is commonly associated with difficulties concentrating, impulsivity and hyperactivity. However, new research suggests that its consequences may extend far beyond everyday challenges, potentially increasing the risk of premature death. The condition affects an estimated 5 percent of children and 2.5 percent of adults worldwide, influencing daily functioning, decision-making and long-term health.
Small lapses in attention can sometimes have serious consequences, particularly when they contribute to traffic accidents, overlooked health problems or delays in seeking medical care. Impulsivity may also increase vulnerability to substance misuse and other risky behaviors. Over time, these factors could contribute to a higher risk of early death compared with people without ADHD.
Large review analyzes global data
A major systematic review published in JAMA Network Open provides further evidence of an association between ADHD and increased mortality. Led by researchers in the United Kingdom, the analysis examined 19 studies published between 2012 and 2025, drawing on data from North America, Europe and Asia.
Together, the studies included approximately 15.9 million people from countries such as the United States, Canada, Sweden, Taiwan, the United Kingdom, Finland and Denmark. Although the individual investigations differed in their methods and objectives, they examined relationships between ADHD, its treatment and mortality over time.
The researchers combined results from 12 studies in a meta-analysis, calculating hazard ratios to compare the relative hazard of death between different groups. Pooling the findings allowed the team to identify broader patterns that might be less apparent in smaller individual studies.
Higher mortality risk with ADHD
The analysis found that people diagnosed with ADHD had a 70 percent higher hazard of death from any cause compared with individuals without the disorder. The association was observed across different age groups and among both men and women, although the magnitude of the risk varied between studies.
Suicide was an important contributor to the increased mortality. People with ADHD had a 90 percent higher hazard of death by suicide than those without the condition. The researchers noted that co-occurring depression, substance use disorders and other mental health conditions may contribute to this elevated vulnerability.
Mortality from intentional and unintentional injuries was also associated with ADHD, with a 50 percent higher hazard of death in this category. Such deaths may involve road traffic accidents, accidental overdoses, falls and other incidents in which attention difficulties or impulsive behavior could play a role.
Unlike an earlier review, the new analysis also identified a 30 percent higher hazard of death from natural causes, including cardiovascular disease and other chronic illnesses. The authors suggest that differences in the available datasets, longer follow-up periods and changes in ADHD diagnosis or management may help explain why this association was detected.
Medication tied to lower mortality
One of the study’s most notable findings was an association between ADHD medication use and lower mortality. Across the included research, people with ADHD who received prescribed medication generally had a lower hazard of death from any cause than those who did not receive pharmacological treatment.
The review did not separately evaluate the effects of individual medications, although stimulant drugs remain among the most commonly prescribed treatments for ADHD. Importantly, the researchers emphasized that the observational nature of the evidence prevents them from concluding that medication itself directly reduces mortality.
People receiving ADHD medication may also have more regular contact with healthcare professionals, better access to mental health services or stronger family support. These factors could independently influence survival. Socioeconomic circumstances and differences in national healthcare systems may also affect who receives treatment and how consistently it is maintained.
The authors caution that the findings represent average associations across diverse populations rather than outcomes that necessarily apply to every individual with ADHD. Differences in sex distribution, cultural attitudes toward the condition and access to medical care may influence the results observed in different countries.
Implications for patients and policy
The findings reinforce the importance of recognizing ADHD as a condition with potentially significant long-term health consequences rather than viewing it solely as a behavioral or attention-related difficulty. Earlier diagnosis, careful evaluation of co-occurring conditions and ongoing medical follow-up may help address factors associated with premature mortality.
The researchers suggest that ADHD management should extend beyond improving concentration or performance at school and work. Interventions that address risky behaviors, substance misuse and mental health difficulties may help reduce some of the pathways associated with increased mortality.
Broader social circumstances also deserve attention. Poverty, unstable housing and limited access to healthcare can compound existing vulnerabilities among people with ADHD. These factors may contribute to health inequalities that cannot be explained by ADHD symptoms alone.
Although further research is needed to determine how medications and other interventions influence long-term survival, the findings suggest that comprehensive, sustained care may have benefits extending beyond symptom management. For healthcare professionals, families and policymakers, the study highlights the importance of accessible treatment and long-term support for people living with ADHD.
